| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Borrelia miyamotoi DNA, Real-Time PCR, Miscellaneous
Test Code93795
CPT Codes
87478
Preferred Specimen
1 mL CSF or synovial fluid collected in a sterile leak-proof container
Minimum Volume
0.3 mL
Other Acceptable Specimens
Whole blood collected in: EDTA (lavender-top) or ACD (yellow-top) tube
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
CSF or synovial fluid
Room temperature: 48 hours
Refrigerated: 7 days
Frozen: 30 days
Whole blood
Room temperature: 48 hours
Refrigerated: 7 days
Frozen: 30 days
Room temperature: 48 hours
Refrigerated: 7 days
Frozen: 30 days
Whole blood
Room temperature: 48 hours
Refrigerated: 7 days
Frozen: 30 days
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Whole blood containing heparin as an anticoagulant
Methodology
Real-Time Polymerase Chain Reaction
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by FDA. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Sets up 6 days a week.
Clinical Significance
Persons infected with Borrelia miyamotoi most likely have fever, joint pains, fatigue, and headache, though unlike Lyme disease, rash is uncommon.
The diagnosis of Borrelia miyamotoi is most often made by clinical examination combined with evidence of tick bite (or known or presumed exposure to ticks in endemic areas). Amplification of B. miyamotoi genomic DNA from blood, fluids or tissues confirms the diagnosis.
The diagnosis of Borrelia miyamotoi is most often made by clinical examination combined with evidence of tick bite (or known or presumed exposure to ticks in endemic areas). Amplification of B. miyamotoi genomic DNA from blood, fluids or tissues confirms the diagnosis.
